- As COVID-19 decelerates its growth, Guardant has failed to generate sizable capital gains despite the recent FDA signoff.
- With vaccine hopes rising, the consensus revenue estimates look overly modest and the discount in the trading multiple compared to the past seems unwarranted.
- Counting on a faster recovery driven by new FDA-approval, our sales projection and trading multiple in line with historicals indicate an undervalued stock.
- With prospects for early cancer detection and precision oncology outweighing the pandemic-driven concerns over near-term growth, Guardant is a 'Buy' for us.
For further details see:
Guardant Health: FDA Signoff And Vaccine Optimism To Materialize Gains